drugset

drugset / Trial / NCT00456716

Sorafenib in BAC or Never-Smokers With Lung Adenocarcinoma

NCT00456716 ↗

Phase 2 Completed 5 enrolled Swedish Medical Center Amgen · collab Bayer · collab

Non-randomizedSingle-groupOpen-labelTreatment

Summary

Open label study of sorafenib

Timeline

Start: 2007-03
Primary completion: 2008-12
Completion: 2008-12

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Sorafenib	Small molecule	400 mg	Oral

Indications